Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Chemoradiotherapy for Locally Recurrent Rectal Cancer (JCOG1801)
NCT04288999Phase 3Recruiting
- Sponsor
- National Cancer Center Hospital East
- Start
- Oct 2019
- Primary completion
- Aug 2025
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in rectal cancer (2 arms), sponsored by National Cancer Center Hospital East. Primary endpoint: Local Relapse-Free Survival at 3 years. Started Oct 2019; status: recruiting.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04288999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04288999.